The therapeutic benefit of Diprogenta's dual action may assist with managing both severe inflammation and secondary bacterial infection in conditions where this combination is appropriate. It is commonly used when short-term symptomatic assistance is needed for acute episodes.

Treatment of Severe, Infected Inflammatory Skin Conditions

This medicine is commonly used across conditions presenting with acute episodes of corticosteroid-responsive skin inflammation, such as eczema, various forms of dermatitis, and certain presentations of psoriasis, that also involve susceptible bacteria. The combination is considered relevant for easing the inflammatory and infectious manifestations in situations where patients experience these complicated dermatoses.

The supportive relief it provides for the acute physical signs of irritation is considered relevant. This helps address symptom clusters that include pronounced redness (erythema), noticeable swelling (oedema), and intense itching (pruritus). By addressing these manifestations, it helps maintain a sense of comfort and stability during periods of heightened symptomatic distress.

---

Quick Fact: Relief for Complicated Skin Inflammation
Symptom Domain: Severe, infected inflammatory states and intense pruritus.
Common Scenarios: Applied during phases of increased distress or discomfort associated with acute flares of dermatitis that also present with susceptible bacteria.
Core Benefit: Provides supportive relief that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Regulatory References

1. BPOM (Indonesian Food and Drug Authority) overview

Diprogenta eligibility is strictly defined by regulatory documents, focusing on absolute contraindications and conditional use for high-risk populations. The medicine must not be used by patients with documented hypersensitivity to Betamethasone, Gentamicin, or any components of the formulation.

Prohibited Use (Contraindications)

Official labeling prohibits use in the presence of specific skin infections:

• Most viral diseases of the skin, including herpes simplex, vaccinia, or chicken pox.
• Tuberculosis of the skin, syphilis-related skin manifestations, or fungal infections.
• Rosacea or perioral dermatitis.

Restricted and Conditional Eligibility

Use is not recommended for children younger than 2 years of age. Paediatric patients generally demonstrate greater susceptibility to systemic effects and require cautious, limited use [1.1, 1.6].

• Pregnancy and Lactation: Use during pregnancy is generally not recommended for prolonged periods or on large areas; benefit must justify risk [1.3]. During breastfeeding, application to the breasts is prohibited [1.1].
• Systemic Risk: Use is restricted on large body surface areas, for prolonged time periods, or under occlusive dressings, as this increases systemic absorption [1.3].
• Organ Function: Caution is required in patients with impaired renal function due to the potential for systemic absorption of the Gentamicin component [1.6].
• Application Sites: Use is restricted on the face, groin, or axillae [1.2]. The medicine is not for ophthalmic, oral, or intravaginal use [1.6].

Diprogenta's official interaction profile is structured around the potential for systemic absorption of its two active components, Betamethasone Dipropionate and Gentamicin Sulfate, as noted in regulatory documents.

Drug-Drug Interactions

Interactions affecting the Betamethasone component are primarily pharmacokinetic. Co-administration with strong CYP3A4 inhibitors, such as ritonavir or nirmatrelvir, is documented to increase the systemic concentration (exposure) of Betamethasone by inhibiting its metabolism. Furthermore, using this medicine alongside other corticosteroid-containing products may result in an additive increase in total systemic glucocorticoid exposure.

Interactions affecting the Gentamicin component are pharmacodynamic. The regulatory label advises avoiding co-use with other neurotoxic and/or nephrotoxic drugs, including certain aminoglycosides, vancomycin, and amphotericin B, due to the risk of cumulative organ toxicity. Potent diuretics, such as furosemide or ethacrynic acid, should also be avoided due to the documented risk of increased ototoxicity with systemically absorbed Gentamicin.

Other Product Constraints

A physical interaction constraint is noted with the product's excipients. The petroleum jelly and liquid paraffin in the formulation are documented to diminish the tear resistance of latex condoms if applied to the anogenital area, compromising their integrity. Additionally, hepatic impairment is noted as a population-specific consideration that may increase the risk of serious systemic side effects from the Betamethasone component due to altered clearance.

Modulating Inflammatory Gene Expression

The betamethasone component, a synthetic glucocorticoid, initiates its action by binding to the Glucocorticoid Receptor (GR) inside target cells. This complex moves into the nucleus and modulates gene transcription through two parallel mechanisms: Transrepression (suppressing genes for pro-inflammatory signals like NF-kappaB) and Transactivation (switching on genes for anti-inflammatory proteins like Lipocortin-1). This fundamental change in genetic output suppresses the synthesis of pro-inflammatory chemical mediators.

---

Suppressing Downstream Inflammatory Cascades

The genomic action of betamethasone leads to the inhibition of key enzymes, such as Phospholipase A2 ( PLA2), which is essential for initiating the Arachidonic Acid Cascade. By blocking this upstream process, the formation of numerous downstream pro-inflammatory eicosanoids, including prostaglandins and leukotrienes, is prevented. The resulting vasoconstriction and decreased fluid leakage limit the accumulation of fluid in the tissue; this also reduces the chemical signaling responsible for local nerve irritation.

---

Bactericidal Inhibition of Protein Synthesis

The gentamicin component acts as a bactericidal inhibitor by targeting susceptible aerobic bacteria. It irreversibly binds to the 30S ribosomal subunit within the bacterial cell, causing the messenger RNA (mRNA) to be misread. This results in the synthesis of faulty, non-functional proteins that compromise the structural and functional integrity of the bacterial cell. This mechanistic domain results in bacterial cell death and operates in parallel with the corticosteroid mechanism.

How to Use Diprogenta (CORTICOSTEROIDS) — Administration Guidelines

This section describes the instructions for the administration and dosing of Diprogenta (Betamethasone Dipropionate/Gentamicin Sulfate).

---

Administration Scope

Property	Instruction
Route of Administration	Strictly Topical (dermatologic) use only; it is not approved for internal, oral, or ophthalmic (eye) use.
Dosing Schedule (Adults/Adolescents)	Apply a thin film of the product sufficient to cover the affected skin area. The standard regimen is typically twice daily, once in the morning and once at night.
Preparation Requirements	The product is used as supplied (cream or ointment). The choice between cream (for weeping lesions) and ointment (for dry lesions) is based on the characteristics of the skin condition.

---

Use Protocol and Constraints

Application should generally be limited to a short-term course. For adults and adolescents, treatment should preferably not exceed 2 to 3 consecutive weeks. Therapy should be discontinued promptly when control of the condition is achieved.

Special Procedural Conditions:

• Occlusion: The treated area should not be bandaged or covered with an occlusive dressing unless specifically instructed by a healthcare provider.
• Children (2–12 years): Application duration is restricted to a maximum of 5 to 7 days. The product should ideally not be used in infants and young children.
• Missed Application: If an application is missed, the patient should resume the twice-daily schedule as usual; a double dose is not applied to compensate.

This protocol defines the standardized, time-limited use of the potent topical corticosteroid and antibiotic combination.

Research evidence / Overview of studies for Diprogenta (CORTICOSTEROIDS)

---

Research for Corticosteroid-Responsive Dermatoses Complicated by Infection

Overview of Studies

Research has explored how this combination of a corticosteroid and an antibiotic was studied for conditions characterized by fluctuating or episodic manifestations. These are conditions involving periods of heightened symptoms or when skin inflammation, like eczema or dermatitis, is also complicated by a suspected or confirmed bacterial presence. Studies of this combination therapy was evaluated in observational settings and randomized controlled trials that were studied for outcomes related to physical discomfort, such as redness, swelling, and itching. The overall research describes patterns observed in the studies that focus on outcomes reflecting daily functioning or activity level over defined time intervals. Many of these trials explored short-term symptom changes over periods lasting a few weeks.

Findings Related to Symptom Outcomes

When this combination was studied for conditions involving periods of heightened symptoms, findings generally indicate patterns related to changes measured during the study period. Studies explored the corticosteroid component in research settings involving inflammatory and irritative states of the skin. The antibiotic component was studied for research involving bacteria presence. Some evidence suggests that for outcomes related to systemic or functional imbalance in the skin, patterns observed in the studies are related to the use of the combination. However, research examining the combination versus the corticosteroid used alone show patterns related to non-significant differences for some overall measures of symptom severity. Findings were mixed in some systematic reviews when evaluating whether the antibiotic addition provides additional differences in measured outcomes for all patients with eczema, especially when the presence of a deep bacterial infection was not fully established.

Research Gaps and Uncertainties

Evidence is limited regarding the effects of using this combination over a long period. In many clinical studies, follow-up durations were limited, generally not exceeding several weeks. This means that long-term effects are not fully established, and there is limited information for long-term outcomes or subsequent flare-ups. Comparative evidence is lacking or uncertain in some areas, particularly concerning whether the antibiotic addition provides a measurable advantage over the steroid alone when treating conditions where bacterial involvement is unclear. The research helps contextualize how patients reported their experience, but certainty remains low in many of these comparisons. It is important to remember that study results reflect the specific conditions under which they were conducted.

---

Evidence in Special Populations

Studies in Pediatric Populations (Children)

Research examined the use of potent topical corticosteroids, including components of this combination, in children aged 2 to 12 years. These studies were observed in populations where children may demonstrate greater susceptibility to changes in their body's hormone levels than mature patients. Findings describe that this greater susceptibility was observed in some studies. Research monitored the use of this combination in children for patterns related to changes in certain hormone markers in some observed populations. These studies monitored use in children. Data for certain groups remain insufficient, and results apply only to the populations studied in the trials. The research *provides context but not individual predictions.

Common questions about Diprogenta (CORTICOSTEROIDS) (FAQ)

Q: Why is Diprogenta generally not recommended for use on the face, groin, or underarm areas?

Official warnings describe that use in these areas is generally restricted on facial skin and in skin crease areas like the groin or underarms. This precaution is noted because applying the medicine to these thinner areas can increase the amount of medicine absorbed into the body, which may heighten the potential for side effects.

Q: What are the signs of a potential allergic reaction to Diprogenta that require attention?

If you experience any signs of irritation that were not present before use, or if severe symptoms occur, discontinuation of the medicine is generally indicated. Regulatory information mentions watching for redness, hives, swelling of the face, or difficulty breathing as reactions for which patients are advised to seek medical attention.

Q: Is Diprogenta still effective if the skin condition is not a bacterial infection?

The medicine is indicated for the relief of inflammatory signs associated with corticosteroid-responsive skin conditions. This means the steroid component is studied for its role in managing inflammation, even when bacterial infection is absent. According to official product information, the primary action of the steroid component (Betamethasone) is to reduce swelling, redness, and itching.

Q: What is the difference in effect between Diprogenta cream and Diprogenta ointment?

The official product information specifies different uses for the two formulations. The ointment formulation is described as being suitable for lesions on dry skin, while the cream formulation is typically used for conditions on oily skin or for skin areas that are weeping (oozing fluid).

Q: What is the meaning of 'HPA axis suppression' in relation to Diprogenta?

HPA axis suppression is a serious risk associated with systemic absorption of the corticosteroid component. The term means that the body's Hypothalamic-Pituitary-Adrenal axis, which controls the natural production of certain hormones, may be reduced or suppressed due to the external steroid input.

Q: Is it safe to use Diprogenta on broken, cracked, or severely damaged skin?

Official warnings state that the medicine is not for application to deep skin wounds, puncture wounds, serious burns, raw areas, or cracked/broken skin. Applying the medicine to these areas can increase the risk of systemic absorption.

Q: Does Diprogenta carry a risk of causing 'rebound effects' or 'topical steroid withdrawal syndrome'?

Official documents describe that if the medicine is used continuously for prolonged periods, a steroid withdrawal reaction may occur when stopping treatment. This reaction is characterized by symptoms such as redness, burning, intense itching, and peeling that may extend beyond the original treated area.

Q: Why must the full course of Diprogenta treatment be completed, even if symptoms clear up quickly?

The official administration protocol states that treatment is typically discontinued promptly when control of the condition is achieved. For adults and adolescents, treatment should generally not exceed two to three consecutive weeks, and for children, it should be even shorter.

Q: Could Diprogenta use potentially allow for an overgrowth of fungi or other non-susceptible organisms?

Regulatory precautions state that the use of this medicine may allow for the overgrowth of bacteria or fungi that are not susceptible to the antibiotic (Gentamicin) component. If such a superinfection develops, regulatory documents indicate that the treatment should be discontinued.

Q: Are there any reported visual disturbances associated with the use of Diprogenta?

Official safety documents list visual disturbances as a potential side effect. Specifically, blurred vision has been reported in association with the use of this medicine.

Q: Is Diprogenta known to cause any changes in skin color?

A change in skin color (such as hyperpigmentation or hypopigmentation) has been reported as a side effect in official safety documentation.

Q: Is Diprogenta used to treat conditions like diaper dermatitis or cold sores?

Official documentation prohibits the use of this medicine for most viral diseases, which includes conditions such as cold sores. For children, the use of tight-fitting diapers or plastic pants is generally restricted unless specifically directed by a healthcare provider.

Q: What is the general expectation for how soon a patient should contact a doctor if there is no improvement?

Official regulatory information states that consultation with a healthcare provider is generally indicated if the skin condition worsens or if irritation that was not present before using the medicine is experienced.

Q: What happens if a patient accidentally applies Diprogenta more frequently than recommended?

The official label states that the medicine should not be used more often or for a longer period of time than recommended. Using the medicine too frequently increases the risk that more of the active ingredients will be absorbed into the body, which may heighten the potential for systemic side effects.

Q: What is the possibility of cross-allergenicity with other aminoglycoside antibiotics?

Official precautions state that cross-allergenicity among aminoglycosides (the class of antibiotic containing Gentamicin) has been demonstrated. This means that a person who is allergic to Gentamicin may also be allergic to other antibiotics in the same drug class.

How to Store and Dispose of Diprogenta

Storage of Diprogenta Cream and Ointment must comply with regulatory requirements to preserve product stability.

Official Storage Conditions

The medicine is required to be stored at a temperature at or below 25 °C. It must be protected from both light and moisture and kept in a tightly closed container.

Child Safety and Stability

For safety, the product must be kept out of the reach and sight of children and should be stored locked up. The cream formulation has a defined in-use stability period and must be discarded three months after the date of first opening.

Disposal

Disposal of unused or expired Diprogenta must follow local and national regulations. To protect the environment, the medicine should not be released into wastewater.